Bronchodilators are the cornerstone of pharmacological management of COPD. For patients
whose conditions are not sufficiently controlled by monotherapy, combining bronchodilators …

Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow
limitation and debilitating symptoms. For patients with moderate-to-severe COPD, long …

Background The place of long-acting β agonist/long-acting muscarinic antagonist
(LABA/LAMA) combinations in stable patients with COPD is not well defined. The purpose of …

Chronic obstructive pulmonary disease (COPD) is a major cause of death and disability
worldwide. Inhaled bronchodilators are the mainstay of COPD pharmacological treatment …

Long-acting β 2 agonist bronchodilators (eg formoterol, salmeterol) are a new interesting
therapeutic option for patients with chronic obstructive pulmonary disease (COPD). In the …

Bronchodilators are central to the management of chronic obstructive pulmonary disease
(COPD). Clinical studies combining different classes of bronchodilators, in particular a long …

Background The wide availability of long-acting muscarinic antagonist (LAMA)/long-acting
β2-agonist (LABA) fixed-dose combinations (FDCs) in the absence of head-to-head …

Nowadays there is solid clinical information for combining β 2-agonists and anti-muscarinic
agents, although the nature (additive or synergistic) of the net clinical result obtained by co …

Chronic obstructive pulmonary disease (COPD) represents a significant cause of global
morbidity and mortality, with a substantial economic impact. Recent changes in the Global …

Fixed dose combination (FDC) dual bronchodilators that co‐administer a long acting β2‐
adrenoceptor agonist (LABA) and a long acting muscarinic antagonist (LAMA) are a new …